Trials / Completed
CompletedNCT00241540
Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
Efficacy of Esomeprazole 40 mg Once Daily Versus Placebo & Esomeprazole 20 mg Once Daily Versus Placebo in Treatment for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 808 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a randomised, double-blind, parallel-group and placebo controlled study comparing the efficacy of esomeprazole 40 mg orally qd vs. placebo and esomeprazole 20 mg orally qd vs. placebo when given to patients on continuous use of NSAIDs, including COX-2 selective NSAIDs, for a period of 4 weeks in treatment of relief of upper GI symptoms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Esomeprazole |
Timeline
- Start date
- 2001-01-01
- Primary completion
- 2002-08-01
- Completion
- 2002-08-01
- First posted
- 2005-10-19
- Last updated
- 2011-01-24
Locations
119 sites across 6 countries: United States, Belgium, France, Germany, Hungary, Spain
Source: ClinicalTrials.gov record NCT00241540. Inclusion in this directory is not an endorsement.